73 related articles for article (PubMed ID: 27501959)
1. Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen.
Jung SH; Cho MS; Kim HK; Kim SJ; Kim K; Cheong JW; Kim SJ; Kim JS; Ahn JS; Kim YK; Yang DH; Kim HJ; Lee JJ;
BMC Cancer; 2016 Aug; 16():613. PubMed ID: 27501959
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in understanding multiple myeloma.
Dhakal B; Girnius S; Hari P
F1000Res; 2016; 5():. PubMed ID: 27610224
[TBL] [Abstract][Full Text] [Related]
3. Impact of marital status, insurance status, income, and race/ethnicity on the survival of younger patients diagnosed with multiple myeloma in the United States.
Costa LJ; Brill IK; Brown EE
Cancer; 2016 Oct; 122(20):3183-3190. PubMed ID: 27548407
[TBL] [Abstract][Full Text] [Related]
4. A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System.
Jung SH; Kim K; Kim JS; Kim SJ; Cheong JW; Kim SJ; Ahn JS; Ahn SY; Yang DH; Kim HJ; Lee JJ
Br J Haematol; 2018 Jun; 181(5):707-710. PubMed ID: 28466549
[No Abstract] [Full Text] [Related]
5. Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party.
Kim SJ; Bang SM; Choi YS; Jo DY; Kim JS; Lee H; Eom HS; Yoon DH; Suh C; Lee JJ; Hong J; Lee JH; Koh Y; Kim K; Yoon SS; Min CK;
Blood Res; 2016 Sep; 51(3):193-199. PubMed ID: 27722131
[TBL] [Abstract][Full Text] [Related]
6. A retrospective analysis to examine factors associated with mortality in Medicare beneficiaries newly diagnosed with multiple myeloma.
Yusuf AA; Natwick T; Werther W; Felici D; Mahue M; Bridges KR; Peng Y
Curr Med Res Opin; 2016 Dec; 32(12):1989-1996. PubMed ID: 27532155
[TBL] [Abstract][Full Text] [Related]
7. Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study.
Peña C; Riva E; Schutz N; Tarín-Arzaga L; Martínez-Cordero H; Bove V; Osorio R; Chandía M; Beltrán C; Schulz J; Cardemil D; Contreras C; Vergara CG; Donoso J; Espinoza M; La Rocca G; López-Vidal H; León P; Rojas Hopkins C; Soto P; Aranda S; Torres V; Roa M; Ochoa P; Duarte PJ; Remaggi G; Yantorno S; Corzo A; Zabaljauregui S; Shanley C; Lopresti S; Orlando S; Verri V; Quiroga L; García C; Fernández V; Ramirez J; Molina A; Pacheco M; Mite A; Reyes I; Sabando B; Ramírez F; Sossa C; Abello V; Idrobo H; Galvez Cardenas KM; Saavedra D; Quintero G; Gazitúa R; Gaviria L; Gomez R; Osuna M; Henao-Uribe A; Cantú-Martínez O; Gómez-Almaguer D; García-Navarrete YI; Cruz-Mora A; Cantero-Fortiz Y; Ruiz-Argüelles GJ; Fantl D
Leuk Lymphoma; 2020 Dec; 61(13):3112-3119. PubMed ID: 32844699
[TBL] [Abstract][Full Text] [Related]
8. Significant differences in access to tests and treatments for multiple myeloma between public and private systems in Latin America. Results of a Latin American survey. GELAMM (Grupo de Estudio Latino Americano de Mieloma Múltiple).
Riva E; Schütz N; Peña C; Ruiz-Argüelles G; Hopkins CR; Bove V; Villano F; Andino L; Suárez L; Martínez H; Navarro J; López-Vidal H; Da Costa O; Pineda MR; Rubio Y; Ramirez J; Choque J; Fantl D
Ann Hematol; 2020 May; 99(5):1025-1030. PubMed ID: 32157420
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
Jung KS; Kim K; Kim HJ; Kim SH; Lee JO; Kim JS; Lee JJ; Eom HS; Min CK; Shin HJ
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e97-e104. PubMed ID: 31831372
[TBL] [Abstract][Full Text] [Related]
10. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Facon T; Dimopoulos MA; Meuleman N; Belch A; Mohty M; Chen WM; Kim K; Zamagni E; Rodriguez-Otero P; Renwick W; Rose C; Tempescul A; Boyle E; Manier S; Attal M; Moreau P; Macro M; Leleu X; Lorraine Chretien M; Ludwig H; Guo S; Sturniolo M; Tinel A; Silvia Monzini M; Costa B; Houck V; Hulin C; Yves Mary J
Leukemia; 2020 Jan; 34(1):224-233. PubMed ID: 31427722
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.
Usmani SZ; Schjesvold F; Oriol A; Karlin L; Cavo M; Rifkin RM; Yimer HA; LeBlanc R; Takezako N; McCroskey RD; Lim ABM; Suzuki K; Kosugi H; Grigoriadis G; Avivi I; Facon T; Jagannath S; Lonial S; Ghori RU; Farooqui MZH; Marinello P; San-Miguel J;
Lancet Haematol; 2019 Sep; 6(9):e448-e458. PubMed ID: 31327689
[TBL] [Abstract][Full Text] [Related]
12. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis.
Weisel K; Sonneveld P; Spencer A; Beksac M; Rizzo M; Xu Y; Fahrbach K; Gaudig M; Slavcev M; Dearden L; Lam A
Leuk Lymphoma; 2019 Jan; 60(1):151-162. PubMed ID: 30407092
[TBL] [Abstract][Full Text] [Related]
14. Daratumumab plus lenalidomide and dexamethasone
Dimopoulos MA; San-Miguel J; Belch A; White D; Benboubker L; Cook G; Leiba M; Morton J; Ho PJ; Kim K; Takezako N; Moreau P; Kaufman JL; Sutherland HJ; Lalancette M; Magen H; Iida S; Kim JS; Prince HM; Cochrane T; Oriol A; Bahlis NJ; Chari A; O'Rourke L; Wu K; Schecter JM; Casneuf T; Chiu C; Soong D; Sasser AK; Khokhar NZ; Avet-Loiseau H; Usmani SZ
Haematologica; 2018 Dec; 103(12):2088-2096. PubMed ID: 30237262
[TBL] [Abstract][Full Text] [Related]
15. A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.
San-Miguel JF; Echeveste Gutierrez MA; Špicka I; Mateos MV; Song K; Craig MD; Bladé J; Hájek R; Chen C; Di Bacco A; Estevam J; Gupta N; Byrne C; Lu V; van de Velde H; Lonial S
Haematologica; 2018 Sep; 103(9):1518-1526. PubMed ID: 29954932
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.
Bolli N; Biancon G; Moarii M; Gimondi S; Li Y; de Philippis C; Maura F; Sathiaseelan V; Tai YT; Mudie L; O'Meara S; Raine K; Teague JW; Butler AP; Carniti C; Gerstung M; Bagratuni T; Kastritis E; Dimopoulos M; Corradini P; Anderson KC; Moreau P; Minvielle S; Campbell PJ; Papaemmanuil E; Avet-Loiseau H; Munshi NC
Leukemia; 2018 Dec; 32(12):2604-2616. PubMed ID: 29789651
[TBL] [Abstract][Full Text] [Related]
17. [Lenalidomide and low-dose dexamethasone therapy for Japanese patients with newly diagnosed multiple myeloma: updated results of the MM-025 study].
Ando K; Chou T; Suzuki K; Shinagawa A; Uchida T; Taniwaki M; Hirata H; Ishizawa K; Matsue K; Okamoto S; Otsuka M; Matsumoto M; Iida S; Matsumura I; Ikeda T; Takezako N; Ogaki Y; Midorikawa S; Houck V; Ervin-Haynes A; Terui Y
Rinsho Ketsueki; 2017; 58(11):2219-2226. PubMed ID: 29212972
[TBL] [Abstract][Full Text] [Related]
18. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
Dimopoulos MA; Lonial S; White D; Moreau P; Palumbo A; San-Miguel J; Shpilberg O; Anderson K; Grosicki S; Spicka I; Walter-Croneck A; Magen H; Mateos MV; Belch A; Reece D; Beksac M; Bleickardt E; Poulart V; Sheng J; Sy O; Katz J; Singhal A; Richardson P
Br J Haematol; 2017 Sep; 178(6):896-905. PubMed ID: 28677826
[TBL] [Abstract][Full Text] [Related]
19. A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma.
Kim MK; Kim K; Min CK; Kwak JY; Bae SB; Yoon SS; Lee JJ; Kim KH; Nam SH; Mun YC; Kim HJ; Bae SH; Shin HJ; Lee JH; Park JS; Jeong SH; Lee MH; Kim YS; Lee HS; Park KW; Lee WS; Lee SM; Lee JO; Hyun MS; Jo DY; Lim SN; Lee JH; Cho DY; Do YR; Kim JA; Park SK; Kim JS; Kim SJ; Kim H; Yi HG; Moon JH; Choi CW; Kim SH; Joo YD; Kim HG; Kim BS; Park MR; Song MK; Kim SY
Oncotarget; 2017 Jun; 8(23):37605-37618. PubMed ID: 28402945
[TBL] [Abstract][Full Text] [Related]
20. A real-world data analysis of predictors of early mortality after a diagnosis of multiple myeloma.
Grant SJ; Wildes TM; Rosko AE; Silberstein J; Giri S
Cancer; 2023 Jul; 129(13):2023-2034. PubMed ID: 36989073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
